The CEO and CFO sales are immaterial in size and follow option exercises, consistent with routine tax/vesting-related selling. No bearish read-through. Monitor next quarterly results for any operational or pipeline updates that could drive sentiment.
PCVX drugs
PCVX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 22 $52.11entry
- T+1 · 5mo ago −0.29%α +1.16% · $51.96
- T+5 · 5mo ago +8.46%α +10.53% · $56.52
- T+20 · 4mo ago +7.85%α +8.00% · $56.20
- T+60 · 2mo ago +13.63%α +11.88% · $59.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two top C-suite executives at Vaxcyte (CEO and CFO) sold a combined ~$542K in open-market sales on June 18, 2026, following the exercise of stock options. The sales are small relative to the $7.3B market cap (~0.007%), making them routine and likely tax-related or liquidity-driven. No material bearish signal.
Key Financial Metrics
Key Facts
- CEO Grant Pickering sold 225 shares for ~$11.8K on June 18
- CFO Andrew Guggenhime sold 10,000 shares for $530K on June 18
- Both sales followed option exercises at nominal prices ($0 and $1.79/$5.35)
- Total open-market sales: ~$542K, or 0.007% of $7.3B market cap
- No other insiders made open-market purchases in the window
Financial Impact
~$542K in total open-market sales, trivial relative to $7.3B market cap
Risk Factors
- No material risk from this filing; the sales are too small to signal concern
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PCVX-1781827713751 |
Track record
29 reports on PCVX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +10.87% at T+5 after the Oct 8, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.40 Now $63.37 +1.55% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $64.69 Now $63.37 −2.04% settles Dec 11
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $63.37 −0.81% settles Dec 7
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $63.37 −0.81% settles Dec 7
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $61.92 Now $63.37 +2.34% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $61.92 Now $63.37 +2.34% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $63.37 +4.21% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $63.37 +4.21% settles Dec 2
- Oct 9, 20265w ago 8-K Bearish 6/10 Entry $70.65 to $67.53 Now $63.37 +10.30% ▲ +4.42% +1.15% vs SPY
- Oct 8, 20265w ago 424B5 Bearish 6/10 Entry $71.38 to $63.89 Now $63.37 +11.22% ▲ +10.49% +4.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers